Publications:

---

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.

Journal Of Hematology & Oncology

Jiang, Qian Q; Li, Zongru Z; Qin, Yazhen Y; Li, Weiming W; Xu, Na N; Liu, Bingcheng B; Zhang, Yanli Y; Meng, Li L; Zhu, Huanling H; Du, Xin X; Chen, Suning S; Liang, Yang Y; Hu, Yu Y; Liu, Xiaoli X; Song, Yongping Y; Men, Lichuang L; Chen, Zi Z; Niu, Qian Q; Wang, Hengbang H; Lu, Ming M; Yang, Dajun D; Zhai, Yifan Y; Huang, Xiaojun X

Publication Date: 2022-08-18

Variant appearance in text: HR: L248V

PubMed Link: 35982483

Variant Present in the following documents:

• Main text
• 13045_2022_Article_1334.pdf

View BVdb publication page

---

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.

Targeted Oncology

Castagnetti, Fausto F; Binotto, Gianni G; Capodanno, Isabella I; Billio, Atto A; Calistri, Elisabetta E; Cavazzini, Francesco F; Crugnola, Monica M; Gozzini, Antonella A; Gugliotta, Gabriele G; Krampera, Mauro M; Lucchesi, Alessandro A; Merli, Anna A; Miggiano, Maria Cristina MC; Minotto, Claudia C; Poggiaspalla, Monica M; Salvucci, Marzia M; Scappini, Barbara B; Tiribelli, Mario M; Trabacchi, Elena E; Rosti, Gianantonio G; Galimberti, Sara S; Bonifacio, Massimiliano M

Publication Date: 2021-11

Variant appearance in text: HR: L248V

PubMed Link: 34661826

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.

Asian Pacific Journal Of Cancer Prevention : Apjcp

Iqbal, Zafar Z; Absar, Muhammad M; Mahmood, Amer A; Aleem, Aamer A; Iqbal, Mudassar M; Jameel, Abid A; Akhtar, Tanveer T; Karim, Sajjad S; Rasool, Mahmood M; Mirza, Zeenat Z; Khalid, Muhammad M; Akram, Afia Muhammad AM; Sabar, Muhammad Farooq MF; Khalid, Ahmad M AM; Aljarrah, Khalid K; Iqbal, Janhangir J; Khalid, Muhammad M; Shah, Ijaz H IH; Alanazi, Nawaf N

Publication Date: 2020-12-01

Variant appearance in text: HR: L248V

PubMed Link: 33369447

Variant Present in the following documents:

• Main text
• APJCP-21-3517.pdf

View BVdb publication page

---

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.

American Journal Of Hematology

Cortes, Jorge E JE; Khoury, Hanna J HJ; Kantarjian, Hagop M HM; Lipton, Jeff H JH; Kim, Dong-Wook DW; Schafhausen, Philippe P; Matczak, Ewa E; Leip, Eric E; Noonan, Kay K; Brümmendorf, Tim H TH; Gambacorti-Passerini, Carlo C

Publication Date: 2016-12

Variant appearance in text: HR: L248V

PubMed Link: 27531525

Variant Present in the following documents:

• Main text
• AJH-91-1206.pdf

View BVdb publication page

---

Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

Plos One

Polivkova, Vaclava V; Rohon, Peter P; Klamova, Hana H; Cerna, Olga O; Divoka, Martina M; Curik, Nikola N; Zach, Jan J; Novak, Martin M; Marinov, Iuri I; Soverini, Simona S; Faber, Edgar E; Machova Polakova, Katerina K

Publication Date: 2016

Variant appearance in text: HR: L248V

PubMed Link: 27214026

Variant Present in the following documents:

• Main text

View BVdb publication page

---

[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi

Jiang, Qian Q; Qin, Yazhen Y; Lai, Yueyun Y; Jiang, Hao H; Shi, Hongxia H

Publication Date: 2016-01

Variant appearance in text: HR: L248V

PubMed Link: 26876246

Variant Present in the following documents:

• Main text
• cjh-37-01-007.pdf

View BVdb publication page

---

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Blood

Parker, Wendy T WT; Yeung, David T O DT; Yeoman, Alexandra L AL; Altamura, Haley K HK; Jamison, Bronte A BA; Field, Chani R CR; Hodgson, J Graeme JG; Lustgarten, Stephanie S; Rivera, Victor M VM; Hughes, Timothy P TP; Branford, Susan S

Publication Date: 2016-04-14

Variant appearance in text: HR: L248V

PubMed Link: 26773037

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Plos One

Iqbal, Zafar Z; Aleem, Aamer A; Iqbal, Mudassar M; Naqvi, Mubashar Iqbal MI; Gill, Ammara A; Taj, Abid Sohail AS; Qayyum, Abdul A; ur-Rehman, Najeeb N; Khalid, Ahmad Mukhtar AM; Shah, Ijaz Hussain IH; Khalid, Muhammad M; Haq, Riazul R; Khan, Mahwish M; Baig, Shahid Mahmood SM; Jamil, Abid A; Abbas, Muhammad Naeem MN; Absar, Muhammad M; Mahmood, Amer A; Rasool, Mahmood M; Akhtar, Tanveer T

Publication Date: 2013

Variant appearance in text: HR: L248V

PubMed Link: 23409026

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.

Revista Brasileira De Hematologia E Hemoterapia

Bitencourt, Roberta R; Zalcberg, Ilana I; Louro, Iúri Drumond ID

Publication Date: 2011

Variant appearance in text: HR: L248V

PubMed Link: 23049365

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.

Clinical Lymphoma, Myeloma & Leukemia

Cornelison, A Megan AM; Kantarjian, Hagop H; Cortes, Jorge J; Jabbour, Elias E

Publication Date: 2011-06

Variant appearance in text: HR: L248V

PubMed Link: 22035738

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.

Core Evidence

Jabbour, Elias E; Cortes, Jorge J; Kantarjian, Hagop H

Publication Date: 2010-06-15

Variant appearance in text: HR: L248V

PubMed Link: 20694077

Variant Present in the following documents:

• Main text
• ce-4-207.pdf

View BVdb publication page

---

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.

Clinical Therapeutics

Stein, Brady B; Smith, B Douglas BD

Publication Date: 2010-05

Variant appearance in text: HR: L248V

PubMed Link: 20685492

Variant Present in the following documents:

• Main text

View BVdb publication page

---

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology

Apperley, Jane F JF; Cortes, Jorge E JE; Kim, Dong-Wook DW; Roy, Lydia L; Roboz, Gail J GJ; Rosti, Gianantonio G; Bullorsky, Eduardo O EO; Abruzzese, Elisabetta E; Hochhaus, Andreas A; Heim, Dominik D; de Souza, Carmino A CA; Larson, Richard A RA; Lipton, Jeffrey H JH; Khoury, H Jean HJ; Kim, Hyeoung-Joon HJ; Sillaber, Christian C; Hughes, Timothy P TP; Erben, Philipp P; Van Tornout, Jan J; Stone, Richard M RM

Publication Date: 2009-07-20

Variant appearance in text: HR: L248V

PubMed Link: 19487385

Variant Present in the following documents:

• Main text

View BVdb publication page

---

The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Blood

Oehler, Vivian G VG; Gooley, Ted T; Snyder, David S DS; Johnston, Laura L; Lin, Allen A; Cummings, Carrie C CC; Chu, Su S; Bhatia, Ravi R; Forman, Stephen J SJ; Negrin, Robert S RS; Appelbaum, Frederick R FR; Radich, Jerald P JP

Publication Date: 2007-02-15

Variant appearance in text: HR: L248V

PubMed Link: 17062727

Variant Present in the following documents:

• Main text

View BVdb publication page

---